Breaking News From Pharma & Bio Ingredients
1Q Sales Jump 23% for Novo Nordisk
Posted on 2006-04-28 09:17:00
Driven by a 60% gain in sales of insulin analogs, Novo Nordisk A/S today announced overall first quarter sales rose 23%. Sales of NovoSeven increased by 16%. Sales in North America increased by 32% sales in international operations increased by 56% Net profit decreased by 2% to $195 million.
The company also noted that the phase III program for liraglutide, the once-daily human GLP-1 analog, including around 3,800 type 2 diabetes patients was initiated in February 2006.
Lars Rebien Sorensen, president and CEO, said: "Novo Nordisk had a strong first quarter of 2006 with continuing sales growth globally. We expect 11-13% sales growth for the full year supported by the recent launch of Levemir in the US, where Novo Nordisk is now the only company with a full portfolio of insulin analogs."
Subscribe via RSS
